COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group

COVAD study group

doi:10.1007/s00296-023-05496-y

COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group

COVAD study group

Smt. Kashibai Navale Medical College and General Hospital
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Ministry of Health and Family Welfare
Southport and Ormskirk Hospital NHS Trust
Aga Khan University
Instituto Mexicano del Seguro Social
Royal Melbourne Hospital
Walter and Eliza Hall Institute of Medical Research
University of Melbourne
Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals
Nippon Medical School
Mymensingh Medical College Hospital
LEDTC Clinic
Universidad del Norte
Sofia University St. Kliment Ohridski
Karolinska Institutet
Örebro University
Friedrich-Alexander University Erlangen-Nürnberg
Seth GS Medical College and KEM Hospital
NIHR Leeds Biomedical Research Centre
University of Leeds
Universidade de São Paulo
All India Institute of Medical Sciences, New Delhi
University of Pittsburgh
University of Illinois at Chicago
Royal Wolverhampton Hospitals NHS Trust
University of Manchester
Sandwell and West Birmingham Hospitals NHS Trust

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

To investigate the frequency, profile, and severity of COVID-19 breakthrough infections (BI) in patients with type I diabetes mellitus (T1DM) compared to healthy controls (HC) after vaccination. The second COVID-19 Vaccination in Autoimmune Diseases (COVAD-2) survey is a multinational cross-sectional electronic survey which has collected data on patients suffering from various autoimmune diseases including T1DM. We performed a subgroup analysis on this cohort to investigate COVID-19 BI characteristics in patients with T1DM. Logistic regression with propensity score matching analysis was performed. A total of 9595 individuals were included in the analysis, with 100 patients having T1DM. Among the fully vaccinated cohort, 16 (16%) T1DM patients had one BI and 2 (2%) had two BIs. No morbidities or deaths were reported, except for one patient who required hospitalization with oxygen without admission to intensive care. The frequency, clinical features, and severity of BIs were not significantly different between T1DM patients and HCs after adjustment for confounding factors. Our study did not show any statistically significant differences in the frequency, symptoms, duration, or critical care requirements between T1DM and HCs after COVID-19 vaccination. Further research is needed to identify factors associated with inadequate vaccine response in patients with BIs, especially in patients with autoimmune diseases.

Original language	English
Pages (from-to)	73-80
Number of pages	8
Journal	Rheumatology International
Volume	44
Issue number	1
DOIs	https://doi.org/10.1007/s00296-023-05496-y
State	Published - Jan 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Breakthrough infections
COVID-19
Survey
Type 1 diabetes mellitus
Vaccine

Access to Document

10.1007/s00296-023-05496-y

Cite this

@article{6f91ab9427024d3f82d823f8644e785f,

title = "COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group",

abstract = "To investigate the frequency, profile, and severity of COVID-19 breakthrough infections (BI) in patients with type I diabetes mellitus (T1DM) compared to healthy controls (HC) after vaccination. The second COVID-19 Vaccination in Autoimmune Diseases (COVAD-2) survey is a multinational cross-sectional electronic survey which has collected data on patients suffering from various autoimmune diseases including T1DM. We performed a subgroup analysis on this cohort to investigate COVID-19 BI characteristics in patients with T1DM. Logistic regression with propensity score matching analysis was performed. A total of 9595 individuals were included in the analysis, with 100 patients having T1DM. Among the fully vaccinated cohort, 16 (16\%) T1DM patients had one BI and 2 (2\%) had two BIs. No morbidities or deaths were reported, except for one patient who required hospitalization with oxygen without admission to intensive care. The frequency, clinical features, and severity of BIs were not significantly different between T1DM patients and HCs after adjustment for confounding factors. Our study did not show any statistically significant differences in the frequency, symptoms, duration, or critical care requirements between T1DM and HCs after COVID-19 vaccination. Further research is needed to identify factors associated with inadequate vaccine response in patients with BIs, especially in patients with autoimmune diseases.",

keywords = "Breakthrough infections, COVID-19, Survey, Type 1 diabetes mellitus, Vaccine",

author = "\{COVAD study group\} and Suhrud Panchawagh and Naveen Ravichandran and Bhupen Barman and Arvind Nune and Mahnoor Javaid and Gracia-Ramos, \{Abraham Edgar\} and Jessica Day and Mrudula Joshi and Masataka Kuwana and Sreoshy Saha and Pande, \{Arunkumar R.\} and Caballero-Uribe, \{Carlo Vinicio\} and Tsvetelina Velikova and Ioannis Parodis and Johannes Knitza and Esha Kadam and Tan, \{Ai Lyn\} and Shinjo, \{Samuel Katsuyuki\} and Hiya Boro and Parikshit Sen and Jessica Day and Elena Nikiphorou and Nelly Ziade and Marcin Milchert and Lorenzo Cavagna and Chen, \{Yi Ming\} and Ashima Makol and Vishwesh Agarwal and Aarat Patel and Pauling, \{John D.\} and Chris Wincup and Tehozol, \{Erick Adrian Zamora\} and Serrano, \{Jorge Rojas\} and \{La Torre\}, \{Ignacia Garc{\'i}a De\} and Colunga-Pedraza, \{Iris J.\} and Javier Merayo-Chalico and Chibuzo, \{Okwara Celestine\} and Wanruchada Katchamart and Goo, \{Phonpen Akawatcharangura\} and Russka Shumnalieva and Hoff, \{Leonardo Santos\} and \{El Kibbi\}, Lina and Hussein Halabi and Binit Vaidya and Shaharir, \{Syahrul Sazliyana\} and Hasan, \{ATMTanveer T.M.T.\} and Dzifa Dey and Guti{\'e}rrez, \{Carlos Enrique Toro\} and Lilleker, \{James B.\} and Ghita Harifi",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2024",

month = jan,

doi = "10.1007/s00296-023-05496-y",

language = "English",

volume = "44",

pages = "73--80",

journal = "Rheumatology International",

issn = "0172-8172",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

TY - JOUR

T1 - COVID-19 breakthrough infections in type 1 diabetes mellitus

T2 - a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group

AU - COVAD study group

AU - Panchawagh, Suhrud

AU - Ravichandran, Naveen

AU - Barman, Bhupen

AU - Nune, Arvind

AU - Javaid, Mahnoor

AU - Gracia-Ramos, Abraham Edgar

AU - Day, Jessica

AU - Joshi, Mrudula

AU - Kuwana, Masataka

AU - Saha, Sreoshy

AU - Pande, Arunkumar R.

AU - Caballero-Uribe, Carlo Vinicio

AU - Velikova, Tsvetelina

AU - Parodis, Ioannis

AU - Knitza, Johannes

AU - Kadam, Esha

AU - Tan, Ai Lyn

AU - Shinjo, Samuel Katsuyuki

AU - Boro, Hiya

AU - Sen, Parikshit

AU - Day, Jessica

AU - Nikiphorou, Elena

AU - Ziade, Nelly

AU - Milchert, Marcin

AU - Cavagna, Lorenzo

AU - Chen, Yi Ming

AU - Makol, Ashima

AU - Agarwal, Vishwesh

AU - Patel, Aarat

AU - Pauling, John D.

AU - Wincup, Chris

AU - Tehozol, Erick Adrian Zamora

AU - Serrano, Jorge Rojas

AU - La Torre, Ignacia García De

AU - Colunga-Pedraza, Iris J.

AU - Merayo-Chalico, Javier

AU - Chibuzo, Okwara Celestine

AU - Katchamart, Wanruchada

AU - Goo, Phonpen Akawatcharangura

AU - Shumnalieva, Russka

AU - Hoff, Leonardo Santos

AU - El Kibbi, Lina

AU - Halabi, Hussein

AU - Vaidya, Binit

AU - Shaharir, Syahrul Sazliyana

AU - Hasan, ATMTanveer T.M.T.

AU - Dey, Dzifa

AU - Gutiérrez, Carlos Enrique Toro

AU - Lilleker, James B.

AU - Harifi, Ghita

PY - 2024/1

Y1 - 2024/1

N2 - To investigate the frequency, profile, and severity of COVID-19 breakthrough infections (BI) in patients with type I diabetes mellitus (T1DM) compared to healthy controls (HC) after vaccination. The second COVID-19 Vaccination in Autoimmune Diseases (COVAD-2) survey is a multinational cross-sectional electronic survey which has collected data on patients suffering from various autoimmune diseases including T1DM. We performed a subgroup analysis on this cohort to investigate COVID-19 BI characteristics in patients with T1DM. Logistic regression with propensity score matching analysis was performed. A total of 9595 individuals were included in the analysis, with 100 patients having T1DM. Among the fully vaccinated cohort, 16 (16%) T1DM patients had one BI and 2 (2%) had two BIs. No morbidities or deaths were reported, except for one patient who required hospitalization with oxygen without admission to intensive care. The frequency, clinical features, and severity of BIs were not significantly different between T1DM patients and HCs after adjustment for confounding factors. Our study did not show any statistically significant differences in the frequency, symptoms, duration, or critical care requirements between T1DM and HCs after COVID-19 vaccination. Further research is needed to identify factors associated with inadequate vaccine response in patients with BIs, especially in patients with autoimmune diseases.

AB - To investigate the frequency, profile, and severity of COVID-19 breakthrough infections (BI) in patients with type I diabetes mellitus (T1DM) compared to healthy controls (HC) after vaccination. The second COVID-19 Vaccination in Autoimmune Diseases (COVAD-2) survey is a multinational cross-sectional electronic survey which has collected data on patients suffering from various autoimmune diseases including T1DM. We performed a subgroup analysis on this cohort to investigate COVID-19 BI characteristics in patients with T1DM. Logistic regression with propensity score matching analysis was performed. A total of 9595 individuals were included in the analysis, with 100 patients having T1DM. Among the fully vaccinated cohort, 16 (16%) T1DM patients had one BI and 2 (2%) had two BIs. No morbidities or deaths were reported, except for one patient who required hospitalization with oxygen without admission to intensive care. The frequency, clinical features, and severity of BIs were not significantly different between T1DM patients and HCs after adjustment for confounding factors. Our study did not show any statistically significant differences in the frequency, symptoms, duration, or critical care requirements between T1DM and HCs after COVID-19 vaccination. Further research is needed to identify factors associated with inadequate vaccine response in patients with BIs, especially in patients with autoimmune diseases.

KW - Breakthrough infections

KW - COVID-19

KW - Survey

KW - Type 1 diabetes mellitus

KW - Vaccine

UR - https://www.scopus.com/pages/publications/85181481512

U2 - 10.1007/s00296-023-05496-y

DO - 10.1007/s00296-023-05496-y

M3 - Article

C2 - 38060005

AN - SCOPUS:85181481512

SN - 0172-8172

VL - 44

SP - 73

EP - 80

JO - Rheumatology International

JF - Rheumatology International

IS - 1

ER -

COVID-19 breakthrough infections in type 1 diabetes mellitus: a cross-sectional study by the COVID-19 Vaccination in Autoimmune Diseases (COVAD) Group

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this